The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis  by Yokoyama, Akihiko et al.
Cell, Vol. 123, 207–218, October 21, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.cell.2005.09.025
The Menin Tumor Suppressor Protein
Is an Essential Oncogenic Cofactor
for MLL-Associated Leukemogenesis
Akihiko Yokoyama,1 Tim C.P. Somervaille,1
Kevin S. Smith,1 Orit Rozenblatt-Rosen,2
Matthew Meyerson,2 and Michael L. Cleary1,*
1Department of Pathology
Stanford University School of Medicine
Stanford, California 94305
2Department of Medical Oncology
Dana Farber Cancer Institute
Department of Pathology
Harvard Medical School
Boston, Massachusetts 02115
Summary
The Mixed-Lineage Leukemia (MLL) protein is a his-
tone methyltransferase that is mutated in clinically
and biologically distinctive subsets of acute leuke-
mia. MLL normally associates with a cohort of highly
conserved cofactors to form a macromolecular com-
plex that includes menin, a product of the MEN1 tu-
mor suppressor gene, which is mutated in heritable
and sporadic endocrine tumors. We demonstrate here
that oncogenic MLL fusion proteins retain an ability
to stably associate with menin through a high-affinity,
amino-terminal, conserved binding motif and that this
interaction is required for the initiation of MLL-medi-
ated leukemogenesis. Furthermore, menin is essen-
tial for maintenance of MLL-associated but not other
oncogene induced myeloid transformation. Acute
genetic ablation of menin reverses aberrant Hox gene
expression mediated by MLL-menin promoter-asso-
ciated complexes, and specifically abrogates the
differentiation arrest and oncogenic properties of
MLL-transformed leukemic blasts. These results de-
monstrate that a human oncoprotein is critically de-
pendent on direct physical interaction with a tumor
suppressor protein for its oncogenic activity, vali-
date a potential target for molecular therapy, and sug-
gest central roles for menin in altered epigenetic
functions underlying the pathogenesis of hematopoi-
etic cancers.
Introduction
MLL is a protooncogene that is targeted by chromo-
somal translocations in a diverse subset of hematologic
disorders including acute lymphoid, myeloid, and bi-
phenotypic leukemia and myelodysplastic syndrome,
all of which are generally associated with a poor prog-
nosis (DiMartino and Cleary, 1999 for review). As a con-
sequence of acquired genetic aberrations in these dis-
orders, the MLL protein is fused with one of more than
40 different partners to yield a diverse collection of
chimeric fusion proteins (Mitterbauer-Hohendanner and
Mannhalter, 2004 for review). Despite their remarkable*Correspondence: mcleary@stanford.edudiversity, many fusion partners share an ability to con-
stitutively activate novel transcriptional effector proper-
ties of MLL, which correlates with its oncogenic poten-
tial in experimental models of acute leukemia (Daser
and Rabbitts, 2004; Hess, 2004 for review). The key
transcriptional pathways that are subordinate to both
wild-type and oncogenic MLL proteins include Hox
genes, which are master regulators of cell fate, prolifer-
ation, and morphogenesis (Owens and Hawley, 2002 for
review). During embryogenesis, MLL is required for
maintenance of Hox gene expression to establish proper
body segment identity (Yu et al., 1995; 1998). In the
hematopoietic compartment, lack of MLL is associated
with reduced expansion of progenitors and decreased
Hox gene expression (Ernst et al., 2004a, 2004b; Hess
et al., 1997; Yagi et al., 1998). Conversely, hematopoi-
etic cells transformed by MLL oncoproteins consis-
tently hyperexpress several Hoxa cluster genes, some
of which have been shown to be direct targets of MLL
and key contributors to the pathologic features of MLL-
associated leukemia (Ayton and Cleary, 2003; Kumar et
al., 2004; Nakamura et al., 2002; So et al., 2004; Wang
et al., 2005; Zeisig et al., 2004). Thus, MLL is an impor-
tant regulator of Hox gene expression, particularly dur-
ing hematopoiesis, and its malfunction is associated
with disordered hematopoiesis and acute leukemo-
genesis.
Wild-type MLL is a large, structurally complex protein
whose transcriptional role is mediated in part through
an ability to covalently modify chromatin, thus distin-
guishing it as one of only a few currently known chro-
matin-modifying enzymes that are directly mutated in
human cancers (Schneider et al., 2002 for review). MLL
possesses inherent histone methyltransferase (HMT)
activity, which is specific for lysine 4 of histone H3 (H3-
K4) (Milne et al., 2002; Nakamura et al., 2002), a mark
that is generally associated with transcriptionally active
states of chromatin (Noma et al., 2001; Strahl et al.,
1999), thus providing a molecular basis for the charac-
teristic role of MLL in maintenance, not initiation, of em-
bryonic Hox gene expression (Yu et al., 1998). In this
capacity, MLL associates through its carboxy-terminal
methylase domain with a cohort of proteins that are
highly similar to components of the SET1 histone
methyltransferase complexes of yeast and human, sug-
gesting that all three macromolecular complexes em-
ploy an evolutionarily conserved biochemical mecha-
nism to mediate their H3-K4-specific HMT activities
(Yokoyama et al., 2004). However, oncogenic mutations
that create MLL fusion proteins in human leukemia re-
sult in disruption of the MLL macromolecular complex
with consequent loss of the HMT domain and its asso-
ciated conserved factors.
Menin is a highly specific partner for MLL proteins,
as it is the only known member of the MLL macromo-
lecular complex that is not shared with the SET1 com-
plexes. Menin-containing MLL family HMT complexes
were identified independently by immunopurification of
menin and of MLL (Hughes et al., 2004; Yokoyama et
Cell
208al., 2004). Strikingly, menin remains complexed with on-
cogenic MLL fusion proteins in leukemia cells while
other complex members do not associate with these
fusion proteins (Yokoyama et al., 2004).
Menin was initially identified as a product of the
MEN1 tumor suppressor gene (Chandrasekharappa et
al., 1997), and its loss of function due to a variety of
missense or truncating mutations is observed in herita-
ble as well as sporadic neoplasms of multiple en-
docrine organs (Chandrasekharappa and Teh, 2003 for
review). MEN1 is an essential gene whose absence re-
sults in embryonic lethality at midgestation in the
mouse, whereas heterozygous mice develop a variety
of endocrine tumors associated with somatic loss of
the remaining wild-type allele, consistent with its role
as a classic tumor suppressor gene for the endocrine
lineage (Bertolino et al., 2003a, 2003b; Crabtree et al.,
2001).
Although menin lacks identifiable functional motifs,
it reportedly interacts with a variety of transcriptional
proteins (Chandrasekharappa and Teh, 2003 for review)
in addition to MLL and MLL2. Menin is a postivie regu-
lator of Hox and CDK inhibitor (Cdki) gene expression
and is associated with chromatin at both Hox and Cdki
loci (Hughes et al., 2004; Milne et al., 2005; Yokoyama
et al., 2004). A subset of missense mutations in MEN1
patients abrogates the ability of menin to coprecipitate
with HMT activity, suggesting a possible role for this
activity in tumor suppression (Hughes et al., 2004).
Conversely, the role, if any, of this lineage-specific tu-
mor suppressor protein in hematopoietic malignancies
involving gain-of-function mutations of the MLL HMT
machinery has not been determined.
Here, we demonstrate that menin associates with
MLL fusion proteins on HOX promoters in human leuke-
mia cells, and is necessary for maintenance of HOX
gene expression by MLL oncoproteins. Furthermore,
menin is required for MLL-mediated transformation,
and targeted acute inactivation of menin specifically re-
verses the differentiation arrest and oncogenic poten-
tial of MLL-transformed blasts. These studies support
a unique and novel function for a tumor suppressor
protein as a direct, essential cofactor for a distinctive
group of oncoproteins in their roles as transcriptional
misregulators of critical HOX target genes in acute leu-
kemogenesis.
Results
MLL Oncoproteins Associate with Menin on HOX
Gene Promoters in Human Leukemia Cells
To establish whether MLL oncoproteins associate with
menin on target genes that are critical for MLL-medi-
ated transformation, chromatin immunoprecipitation
(ChIP) assays were performed using human ML-2 leu-
kemia cells. These cells lack a normal MLL gene and
thus exclusively express an MLL-AF6 fusion protein as
a consequence of t(6;11) chromosomal translocation
(Tanabe et al., 1996), in contrast to control cells (REH)
that carry no MLL chromosomal translocation and only
express the processed MLLN and MLLC subunits (Fig-
ure 1A). Immunoprecipitation of MLL-AF6 from ML-2
cells resulted in the coprecipitation of menin demon-
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Rstrating that the two proteins associate with each othern the absence of wild-type MLL (Figure 1A, lane 4).
hIP analysis using anti-MLLN and anti-menin antibod-
es demonstrated that MLL-AF6 and menin were both
resent at upstream sites of the HOXA7, HOXA9, and
OXA10 promoters, but neither protein was associated
ith the b-ACTIN or GAPDH promoters (Figure 1B).
OXA9 in particular is highly expressed in MLL-associ-
ted leukemias (Armstrong et al., 2002; Rozovskaia et
l., 2001; Yeoh et al., 2002) and has major influence on
heir incidence and/or phenotype in mouse models (Ay-
on and Cleary, 2003; Kumar et al., 2004; So et al., 2004;
ang et al., 2005). Previous studies showed that the
xpression of HOXA9 in HeLa cells is dependent on the
resence of both wild-type MLL and menin (Yokoyama
t al., 2004). The current results demonstrate that
OXA7, HOXA9, and HOXA10 are direct target genes
or MLL oncoproteins in association with menin, which
olocalize on these promoters in human leukemia cells.
LL Fusion Proteins Interact with Menin
hrough Multiple Domains
o establish the structural requirements for MLL-menin
nteraction, a series of deletion mutations (Figure 2A)
as introduced into the MLL portion of MLL-ENL (ME)
nd evaluated in IP-Western blot analysis for their ef-
ects on the ability of ME to interact with endogenous
enin. Immunoprecipitation of an initial series of FLAG-
agged mutant ME proteins from nuclear extracts of
ransiently transfected cells revealed that a domain
onferring strong interaction with endogenous menin
esided within the first 331 amino acids of MLL (Figure
B). A second, much weaker interaction domain was
ontained in a region spanning residues 640–1251 of
LL. More refined mutational analysis showed that the
igh-affinity interaction domain for menin localized
ithin the first 35 amino acids of MLL (Figure 2C).
dentification of a Conserved, High-Affinity Menin
inding Motif (hMBM) in MLL
o further define the high-affinity menin binding motif,
series of GAL4 fusion proteins containing different 10-
mino-acid segments of MLL were tested for their abil-
ty to associate with menin. Immunoprecipitation of the
LAG-tagged GAL4 fusion proteins from transiently
ransfected cells revealed that three peptides (spanning
mino acids 1–10, 4–13, and 6–15 of MLL, respectively)
oprecipitated endogenous menin (Figure 2D). Se-
uence alignment (Figure 2E) revealed that the region
f overlap (MLL amino acids 6–10) among all three pep-
ides was conserved in pufferfish (fugu) MLL (Caldas et
l., 1998) as well as MLL2 (amino acids 17–21, Hunts-
an et al., 1999), a homolog of MLL that biochemically
ssociates with menin (Hughes et al., 2004). To confirm
hat this consensus sequence (RXRFP) is a high-affinity
enin binding motif, it was removed by interstitial dele-
ion of amino acids 6–10 within the ME and MLL-GAS7
MG) oncoproteins (deletion mutants MEd and MGd, re-
pectively). Immunoprecipitation analysis revealed that
either mutant oncoprotein was capable of high-affinity
nteraction with menin, in contrast to the respective in-
act fusion proteins (Figure 2F). Thus, the consensus
XRFP sequence near the amino terminus of MLL con-stitutes a high-affinity menin binding motif (hMBM).
Requirement for Menin in MLL Oncogenesis
209Figure 1. MLL Oncoproteins Associate with
Menin on HOX Gene Promoters In Vivo
(A) Proteins present in nuclear extracts
(lanes 1 and 2) or immunoprecipitates (lanes
3 and 4) were separated by SDS-PAGE and
immunoblotted with antibodies specific for
MLLN (top panel), MLLC (upper middle
panel), menin (lower middle panel), or actin
(bottom panel). REH cells (lane 1) contain
wild-type MLLN and MLLC subunits, whereas
ML-2 cells (lane 2) contain only the MLL-AF6
fusion protein due to presence of a translo-
cated MLL gene and deletion of the wild-
type MLL gene. Immunoprecipitation with an
anti-MLLN antibody (rpN1) demonstrates co-
IP of menin with MLL-AF6 (lane 4) compared
to the control IP with anti-dmMyb antibody
(lane 3). Molecular sizes of protein markers
are shown on the left. Asterisk indicates a
degradation product of MLL-AF6.
(B) Chromatin immunoprecipitation assay
was performed to assess the coassociation
of menin and MLL oncoproteins on various HOX gene promoters of human ML-2 leukemia cells. Chromatin was immunoprecipitated with
antibodies specific for dmMyb (lane3), MLLN (lane 4) and menin (lane 5) as well as a no antibody control (lane 2). The presence of HOX
promoter DNA in the chromatin precipitates was assessed by PCR along with those of b-ACTIN and GAPDH.MLL Oncoproteins Are Dependent on Interaction
with Menin for Transformation
of Myeloid Progenitors
To determine if association with menin is required for
MLL-associated leukemogenesis, an MLL fusion pro-
tein lacking the hMBM (MEd) was tested for its onco-
genic potential in vitro and in vivo. Primary myeloid
stem/progenitor cells were harvested from mouse bone
marrow, transduced with MLL fusion proteins, and then
assessed for their clonogenic properties in methylcellu-
lose serial replating assays and ability to induce leukemia
in syngeneic recipient mice (Figure 3A). Cells transduced
with the intact ME oncogene displayed enhanced
clonogenic activity as evidenced by their ability to gen-
erate colonies through three rounds of plating in
methylcellulose medium, a hallmark feature of MLL-
transformed cells (Lavau et al., 1997). In contrast, pro-
genitors transduced with MEd, which is incapable of
binding to menin with high affinity, exhausted their clo-
nogenic activity by the second round of plating (Figure
3B), similar to normal progenitors or those transduced
with vector alone. Comparable expression of the trans-
duced genes was confirmed by Western blot analysis
of cells from first-round cultures (Figure 3C). Trans-
duced cells established long-term engraftment of syn-
geneic recipient mice following transplantation (Figure
3D), but MEd-expressing cells did not induce acute my-
eloid leukemia (Figure 3E), in contrast to ME-trans-
duced cells, which induced leukemia similar to previous
studies (Ayton and Cleary, 2003; Lavau et al., 1997).
Thus, high-affinity interaction with menin is required for
MLL oncoproteins to induce oncogenic transformation
of myeloid progenitors.
Menin Is Specifically Required for Maintenance
of Transformation Mediated by MLL Oncoproteins
A general role for menin in myeloid transformation and
the need for its continuous presence in the mainte-
nance of MLL-associated leukemogenesis were inves-
tigated. Myeloid progenitors were isolated from thebone marrow of wild-type (wt) mice or mice homozy-
gous for a floxed Men1 gene (f/f) and then transduced
with various MLL oncogenes including ME, MG, and
MA (MLL-AF10) that transform hematopoietic cells by
diverse molecular mechanisms (So et al., 2003; Nie et
al., 2003; Okada et al., 2005). The unrelated E2A-HLF
(EH) oncogene was employed for comparison (Figure
4A). All of the genes induced continuous clonogenic ac-
tivity of myeloid progenitors in serial replating assay
and oncoprotein expression was confirmed by Western
blot analysis (Figure 4B). After establishment of stable
transformation following more than three replatings in
methylcellulose medium, the cells were transduced
with a retrovirus (MSCV-puro) expressing a conditional
Cre-ERtam fusion protein (CER) whose recombinase ac-
tivity is activated by 4-hydroxy-tamoxifen (4-OHT) to
acutely inactivate the Men1 gene. Secondarily trans-
duced cells were selected in the presence of puromycin
and then relative clonogenic activity compared to vec-
tor control was assessed in the subsequent round of
plating in the presence of 4-OHT to activate the Cre
recombinase (Figure 4A). The genotype and menin ex-
pression with or without Cre recombinase induction 48
hr after 4-OHT addition were assessed by PCR and
Western blotting, respectively (Figures 4C and 4D).
Acute loss of menin in ME-transformed menin-floxed
progenitors abrogated their clonogenic activity, whereas
ME-transformed wild-type cells were unaffected (Figure
4E). The few colonies present in cultures of ME-trans-
formed/CER-transduced Men1 floxed cells were small
with diffuse morphology suggestive of a more dif-
ferentiated phenotype in contrast to the large blast-
type control colonies (Figure 4F). Other MLL oncogene-
transformed cells (MA and MG) lost their clonogenic
activity upon deletion of menin, as well (Figure 4E).
Conversely, EH-transformed cells were unaffected by
acute loss of menin and continued to produce colonies
in methylcellulose medium (Figure 4E) with morpholo-
gies that were indistinguishable with or without Cre ac-
tivation (data not shown). Therefore, menin is neces-
sary for maintenance of transformation induced by MLL
Cell
210Figure 2. A Conserved, High-Affinity Menin Binding Motif Resides at the Amino Terminus of MLL
(A) Various ME or MG deletion mutants (shown schematically) containing a FLAG epitope tag at their N termini were expressed in 293T cells
by transient transfection. Nuclear extracts prepared from transfectants were subjected to immunoprecipitation with anti-FLAG antibody
affinity beads. High-affinity menin binding capacities are indicated on the right.
(B and C) Immunoprecipitated proteins were separated by SDS-PAGE and immunoblotted with anti-FLAG (upper panel) or anti-menin (bottom
panel) antibodies. Lane 1 in each panel contains 1% input of ME transfectant. Molecular sizes of protein markers are shown on the left.
Arrows in panel (B) denote mutant MLL proteins.
(D) GAL4 fusion proteins containing different 10 amino acid segments of the first 35 residues of human MLL (and a FLAG epitope tag) were
analyzed for their binding capacity with menin (MLL 1/331 served as a positive control, lane 2). The immunoprecipitates were separated in
SDS-PAGE gel and immunoblotted with anti-FLAG (upper panel) or anti-menin (bottom panel) antibodies. Lane 1 contains 2% input of MLL
1/133. Molecular sizes of protein markers are shown on the left.
(E) The amino acid sequences employed in panel (D) are aligned with fugu MLL and human MLL2. Binding capacity with menin is shown as
+ or − on the right. A consensus high-affinity menin binding motif (hMBM) is indicated at the bottom.
(F) Internal deletion mutants (shown schematically in panel [A]) of ME and MG lacking the hMBM (amino acids 6–10) were analyzed for their
high-affinity binding capacity (+ or −) with menin using methods as described above. Immunoprecipitates were separated in SDS-PAGE gel
and immunoblotted with anti-FLAG (upper panel) or anti-menin (bottom panel) antibodies. Lane 1 contains 1% input of ME transfectant.
Molecular sizes of protein markers are shown on the left.
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211Figure 3. Interaction with Menin Is Required for Transformation by MLL-ENL
(A) Schematic depiction of experimental scheme. BM progenitor/stem cells (c-kit+) from C57BL/6 mice transgenic for eGFP were transduced
with ME or MEd and used for serial myeloid replating assays, or cultured in liquid media containing G418 for 5 days, and then transplanted
into lethally irradiated recipient mice.
(B) The results of myeloid progenitor transformation assays through three rounds of serial methylcellulose culture are shown as CFU (colony
forming unit) per 104 plated cells. Error bars indicate standard deviations of three independent experiments.
(C) Western blot analysis shows expression of ME and MEd in lysates of transduced cells from first round colonies. Endogenous wild-type
MLLN served as a loading control.
(D) FACS analyses of cells from bone marrow aspirates performed 61 days posttransplantation demonstrate the presence of eGFP-expressing
TER119-negative cells in mice transplanted with ME- or MEd-transduced hematopoietic progenitors, confirming their successful engraftment.
The average percentage of eGFP positive cells in the entire ME cohort (17.4 ± 5.6%) was higher than the MEd cohort (3.6 ± 1.7%) indicative
of an expanding population of preleukemic cells in the ME-transduced recipients.
(E) Survival curves for mice transplanted with ME (solid line)- or MEd (dashed line)-transduced cells are shown. Presence of acute myeloid
leukemia was confirmed by peripheral blood leukocyte counts, FACS analyses, and/or necropsy.oncoproteins, in contrast to the EH oncoprotein, which
appeared to be entirely independent of menin. Taken
together, our results indicate a specific, as opposed to
general, menin requirement for both the initiation and
maintenance of transformation by MLL oncogenes.
Loss of Menin Relieves the Differentiation Block
of MLL-Transformed Leukemic Blasts
The consequences of acute menin loss in MLL-trans-
formed cells were further investigated in myeloid pro-
genitors that were transformed by either the ME or MA
oncogenes and coexpressed CER. Without inactivation
of the Men1 gene, the cultures were comprised pre-
dominantly of Mac1int cells with the morphologic fea-tures of blasts (Figures 5A–5C). Within 48 hr following
acute Men1 deletion, the proportion of blasts was
markedly reduced (e.g., 48% to 8% for ME/CER), and
the cultures contained mostly Mac1hi cells with mature
or maturing cytologic features (Figures 5A–5C). DNA
content analysis showed that within 48 hr of Men1 dele-
tion, there was an increase of the G0/G1 population and
a reduction in S-G2/M phase cells (Figure 5D) and cells
with metaphase chromatin (data not shown), consistent
with the inability of Men1 null MLL-transformed cells to
proliferate and generate CFU in culture (Figure 4E). MA-
transformed cells also showed accumulation at G0/G1
phase while the vector control or wild-type cells did
not (data not shown). Taken together, these analyses
Cell
212Figure 4. Menin Is Required to Maintain the MLL-Transformed Phenotype of Myeloid Progenitors
(A) BM progenitor/stem cells harvested from wild-type mice (wt) or mice homozygous for a floxed Men1 allele (f/f) were transduced with
various MLL oncogenes (ME, MA, and MG) or the EH oncogene. Immortalized cells from the third to seventh round of in vitro plating were
then transduced a second time with either vector alone (v) or a Cre-ERtam-expressing (CER) virus, and selected in the presence of puromycin
for one round. The resistant cells were then assessed for their clonogenic potentials in the subsequent round of plating in methylcellulose in
the presence of 1 nM 4-OHT.
(B) Oncoprotein expression was confirmed by Western blotting using anti-MLLN (upper panel) or anti-E2a (lower panel) antibodies.
(C) The Men1 genotypes of cells present in methylcellulose cultures following secondary retroviral transductions were determined by PCR.
(D) Menin levels were assessed by Western blot analysis using an anti-menin antibody, which demonstrated the rapid reduction of menin in
Men1 floxed (f/f) cells 48 hr after activation of CER when compared with wt cells or vector-transduced cells.
(E) Relative numbers of colonies generated by CER-transduced cells compared to vector control-transduced cells cultured in the presence
of 4-OHT for 5 days were examined for each construct (indicated below the panel). Error bars denote standard deviations of three independent
experiments. MLL oncogene-transformed, menin-deleted cells show severely reduced clonogenic activity in contrast to EH-transformed cells.
(F) Representative morphologies are shown for colonies obtained for ME-transformed/CER (or empty vector)-transduced wt or Men1 floxed
(f/f) cells following the second round of plating in the presence of 4-OHT.indicate that myeloid blasts transformed by MLL onco-
proteins are critically dependent on menin to effectively
maintain their undifferentiated state, as well as their en-
hanced cycling and clonogenic properties. These fea-
tures are similar to those associated with acute inacti-
vation of ME in transformed myeloid progenitors (Ayton
and Cleary, 2003; Zeisig et al., 2004), providing further
support that MLL oncoproteins work together with
menin in myeloid leukemogenesis.
Menin Is Required for Maintenance of Hox Gene
Expression by MLL Fusion Proteins
Given the specific dependence on menin for MLL-
mediated myeloid transformation and the coassocia-
tion of menin with MLL oncoproteins on HOX gene pro-
moters in human leukemia cells, we investigated the
contributions of menin to Hox gene expression in MLL-
transformed murine cells. HOXA cluster genes, particu-
larly HOXA7 and HOXA9, are consistently and highly
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fexpressed in MLL-associated human and mouse leuke-ia, and their expression is dependent on functional
LL fusion proteins (Armstrong et al., 2002; Ayton and
leary, 2003; Kumar et al., 2004; Rozovskaia et al.,
001; Yeoh et al., 2002; Zeisig et al., 2004). Therefore,
oxa gene expression was evaluated by quantitative
eal-time PCR in murine myeloid progenitors one week
ollowing transduction with the ME oncogene or a mu-
ant version lacking the hMBM (MEd). Hoxa genes were
xpressed at 3- to 10-fold higher levels in ME- com-
ared to MEd-transduced cells (Figure 6A), suggesting
hat maintenance of high-level Hox gene expression by
E required its association with menin. As shown pre-
iously (Figure 3B), MEd-transduced cells were unable
o maintain clonogenic activity when plated in methyl-
ellulose medium, consistent with the association of
ustained Hox gene expression with MLL-mediated
ransformation (Ayton and Cleary, 2003). Expression of
he same Hoxa genes was also analyzed in ME-trans-
ormed Men1 floxed cells 48 hr after Men1 was acutelydeleted by activation of Cre recombinase. The high
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213Figure 5. Acute Loss of Menin Results in Differentiation and Reduced Cycling of MLL-Transformed Myeloid Leukemia Blasts
(A) ME-transformed cells homozygous for a floxed Men1 gene (f/f) were secondarily transduced with a retrovirus expressing CER or empty
vector (v) and cultured in the presence of 4-OHT. Cytopreparations of cells harvested after 48 hr in 4-OHT were stained with May Grunwald-
Giemsa.
(B) The percentages of cells with morphologic features of blasts, maturing cells, or macrophages are indicated as determined by microscopic
evaluation. The differentiation of wt cells was unaffected by CER (data not shown).
(C) FACS analysis of CD11b (Mac-1) expression was performed on ME or MA-transformed/CER-transduced Men1 floxed (f/f) cells 48 hr after
addition of 4-OHT. ME-transformed wt cells served as a negative control. Each panel contains data for unstained (green), empty vector-
transduced (blue), or CER-transduced (red) cells.
(D) DNA content of ME-transformed/CER-transduced cells with wild-type (wt) or Men1 floxed (f/f) genotype was analyzed 48 hr after addition
of 4-OHT. Percentages of G0/G1 population (2n) and S-G2/M population (2n < 4n) are indicated (105 cells analyzed). ME-transformed cells
accumulate at G0/G1 after loss of menin. Representative data are shown for three independent experiments.levels of expression for Hoxa7 and Hoxa9 in ME-trans-
formed cells rapidly decreased to approximately 40%
of their original levels within 48 hr following acute loss
of menin (Figure 6C), demonstrating its requirement for
maintenance of Hox gene expression. ChIP performed
on ME-transformed cells confirmed that Hoxa9 is a di-
rect target gene of menin in this context (Figure 6C). On
the other hand, expression of the CDK inhibitor p27Kip1,
reported as a direct target gene of MLL and menin in
fibroblasts (Milne et al., 2005), was not affected by loss
of menin in myeloid progenitors (Figures 6A and 6B),
indicating that it is not a target gene of MLL oncopro-
teins in myeloid progenitors. Therefore, menin is re-
quired for Hoxa gene expression mediated by onco-
genic MLL fusion proteins in myeloid progenitors,
providing a molecular basis for its essential role in MLL-
mediated transformation.
Discussion
The Menin Tumor Suppressor Protein Is an Essential
Leukemogenic and Transcriptional Cofactor
for MLL Oncoproteins
Menin is a product of the MEN1 tumor suppressor
gene, whose inactivation is associated with a variety ofheritable and sporadic endocrine tumors (Chandra-
sekharappa and Teh, 2003 for review). It functions as
a classic tumor suppressor protein for the endocrine
lineage as confirmed by genetic studies in humans and
mice (Bertolino et al., 2003b; Chandrasekharappa et al.,
1997; Crabtree et al., 2001). We have previously shown
that menin is a component of a macromolecular com-
plex containing MLL, which is a leukemic protoonco-
genic protein, and that this complex participates in
maintenance of Hox gene expression (Yokoyama et al.,
2004). The unexpected biochemical association of a tu-
mor suppressor protein with a protooncogenic protein
raised important questions regarding their respective
roles in endocrine and hematologic cancers. The issue
specifically addressed in the current study was whether
MLL oncoproteins require, or alternatively bypass,
menin molecular function in leukemia pathogenesis.
Our results demonstrate that MLL oncoproteins are
critically dependent on menin, indicating that in addi-
tion to its tumor suppressor role, menin also provides
an essential function on an oncogenic pathway. Loss
of the ability to associate with menin abrogates the on-
cogenic properties of MLL in vitro and in vivo, and MLL-
transformed cells require the continued presence of
menin, indicating that it is necessary for both the initia-
Cell
214Figure 6. Menin Is Required for Maintenance of Hox Gene Expres-
sion in MLL-Transformed Cells
(A) Expression of the Hoxa7, Hoxa9 and p27KIP1 genes (indicated
at the tops of the respective panels) normalized to b-actin was de-
termined by quantitative real-time PCR analysis of cells that had
been transduced with vector (v), ME, or MEd and cultured in
methylcellulose medium for 1 week. Percent expression relative to
ME-transduced cells is depicted; error bars represent the standard
deviations of triplicate analyses. Hox gene expression was not
maintained in cells transduced by MLL fusion proteins unable to
bind menin.
(B) ME-transformed wt or Men1 floxed (f/f) cells transduced with
empty vector (v) or CER were analyzed 48 hr after addition of
4-OHT for expression levels of Hoxa7, Hoxa9, and p27KIP1 tran-
scripts (indicated at the tops of the respective panels) relative to
b-actin by quantitative real time PCR. Percent expression is de-
picted relative to ME-transformed/vector-transduced Men1 floxed
(f/f) cells with error bars representing the standard deviation of trip-
licate analyses. Hox gene expression was not maintained in cells
lacking menin.
(C) ChIP was performed using ME-transformed cells. DNA frag-
ments upstream of the first ATG of the Hoxa9 and b-actin genes
were amplified from anti-menin (BL342) immunoprecipitates (or 1%
of input DNA as a control). Menin localized at the Hoxa9 but not
the b-actin promoter.
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ttion and maintenance of MLL-mediated oncogenic
transformation. This does not reflect a generalized re-
quirement for menin in myeloid progenitor transforma-
tion since the unrelated E2A-HLF oncoprotein is not de-
pendent on menin for its oncogenic effects under
t
(
p
s
sidentical experimental conditions. Therefore, menin isspecific and essential oncogenic cofactor for MLL-
ediated leukemogenesis.
The demonstration that menin associates with MLL
ncoproteins on the HOXA9 promoter in leukemia cells
uggested that they work together for transcriptional
egulation of biologically relevant target genes, thereby
roviding a molecular basis for a menin requirement in
LL-mediated oncogenesis. Their colocalization on
ox promoters suggests that the menin requirement for
ransformation is unlikely to simply reflect its dominant-
egative sequestration by MLL oncoproteins, although
e cannot unequivocally rule out more complex sce-
arios that may in part involve menin sequestration. In
upport of a cofactor role for menin, expression of sev-
ral Hoxa cluster genes is dramatically reduced in cells
ransduced with MLL oncoproteins lacking a menin
inding motif and in MLL-transformed cells acutely de-
leted of menin. Hoxa9 in particular influences the inci-
ence and/or phenotype of MLL leukemias, demon-
trating that constitutive expression of Hox genes by
enin/MLL fusion protein complexes is an important
spect of MLL leukemogenesis. Furthermore, a simple
ominant-negative mechanism should not be affected
y menin deletion, which would otherwise be redun-
ant with MLL-mediated sequestration. Thus, menin
ppears to be a transcriptional and oncogenic cofactor
hat is required for transformation of myeloid progeni-
ors as well as transcriptional misregulation of Hox
enes by MLL oncoproteins.
ual Roles for Menin as a Tumor Suppressor
nd an Oncogenic Cofactor
lthough there are clear examples of oncoproteins
e.g., Mdm2) whose transforming activities are medi-
ted by functional inactivation of subordinate tumor
uppressor proteins (Vargas et al., 2003 for review), the
ependence of an oncoprotein on direct physical in-
eraction with a tumor suppressor protein as a neces-
ary cofactor for its oncogenic activity has no pre-
edent to our knowledge. Current data support a
rovisional model for menin as a component of the MLL
acromolecular HMT complex, which localizes to Hox
nd other critical target genes to participate in their
ormal dynamic regulation in response to upstream
rowth and differentiation signals. MLL oncoproteins
arboring gain-of-function mutations retain a critical
ependence on menin but are devoid of other known
LL-associated factors and may no longer respond to
pstream signals, thus maintaining constitutively high
evels of subordinate gene expression likely through
ranscriptional effector functions of their fusion part-
ers (Figure 7). Misregulation of genes such as HoxA9,
hich has oncogenic properties when hyperexpressed
n hematopoietic progenitors (Kroon et al., 1998; Schna-
el et al., 2000), would complete an oncogenic circuit.
In endocrine cancers, on the other hand, menin loss
f function results from truncating or missense muta-
ions, several of which have been shown to abrogate
he ability of menin to coprecipitate with HMT activity
Hughes et al., 2004). Loss of menin function, as op-
osed to MLL gain of function in leukemias, has been
hown to compromise subordinate Hox gene expres-
ion, such as Hoxc8 and HOXA9 in menin-deficientMEFs and HeLa cells, respectively (Hughes et al., 2004;
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215Figure 7. Menin-Dependent Mechanisms for Target Gene Regulation by Wild-Type and Oncogenic MLL Fusion Proteins Provide a Pathogenic
Model for MLL-Associated LeukemogenesisYokoyama et al., 2004). Although HOX gene misregula-
tion may contribute to endocrine neoplasia, menin-MLL
HMT complexes also positively regulate genes encod-
ing anti-proliferation factors, such as p27Kip1 and
p18Ink4c. Their expression is compromised in the ab-
sence of menin in immortalized fibroblasts (Milne et al.,
2005), although not in myeloid progenitors transformed
by MLL oncoproteins (current study). Menin is also
implicated in negative gene regulation through associa-
tion with the Sin3/HDAC corepressor complex. Menin-
mediated tethering of this chromatin-modifying ma-
chinery to JunD alters its transcriptional properties,
converting JunD from a growth promoter to a growth
suppressor (Agarwal et al., 1999, 2003; Kim et al., 2003).
Thus, the consequences of menin loss are complex and
apparently cell context, target gene, and coregulator
dependent. Taken together, these observations suggest
the broader hypothesis that contrasting functions of
menin as a tumor suppressor versus oncogenic cofac-
tor may be different manifestations of its critical roles in
tethering or targeting a subset of chromatin modifying
complexes to specific promoters.
Acute Loss of Menin Specifically Targets Leukemia
Blasts Transformed by MLL Oncoproteins and
Provides a Rationale for Molecular Therapy
Our studies show that menin is specifically required for
MLL-transformed blasts to maintain their oncogenic
properties raising the possibility that molecular tar-
geting of MLL-menin interaction may be an effective
therapeutic approach. Unlike conventional protein-pro-
tein interactions, the MLL-menin interaction appears to
involve multiple MLL surfaces with at least two widely
separate menin interaction domains. A small highly con-served N-terminal MLL motif (hMBM) mediates high-
affinity binding with menin, whereas a second, less
well-defined domain that resides within residues 640–
1251 mediates low-affinity interaction. Although the
physiological significance of low-affinity binding with
menin is unclear, it is not sufficient for maintenance of
high-level target gene expression or transformation by
MLL oncoproteins. Conversely, deletion of a mere five
amino acids of the hMBM abrogates the ability of MLL
oncoproteins to maintain HOX gene expression and in-
duce acute myeloid leukemia. Importantly, menin is re-
quired for long-term maintenance of MLL-mediated on-
cogenesis. Its acute inactivation in MLL-transformed
cells results in the rapid loss of leukemia blasts, which
lose their clonogenic potential, and undergo differentia-
tion, a phenotype similar to that associated with condi-
tional inactivation of MLL-ENL itself (Ayton and Cleary,
2003; Zeisig et al., 2004). These results credential the
hMBM as a therapeutic target and suggest that leu-
kemias that are dependent on MLL function for misregu-
lation of multiple subordinate HOX genes should be
amenable to selective targeting by small molecule an-
tagonists of MLL-menin interaction. Efforts to isolate
such compounds seem well warranted and may pro-
vide a treatment modality for a subset of leukemia that
currently responds poorly to available therapies.
Experimental Procedures
Cell Culture
Phoenix and 293T cells were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% fetal calf serum
(FCS). REH and ML-2 cells were cultured in RPMI 1640 medium
supplemented with 10% FCS.
Cell
216Immunoprecipitation and Western Blotting
Preparation of nuclear extracts, immunoprecipitation analysis, and
Western blotting were performed as previously described (Yoko-
yama et al., 2002, 2004). Primary antibodies included: mouse mono-
clonals specific for MLLN (mmN4.4), MLLC (mmC2.1) and E2A (YAE);
rabbit anti-MLLN (rpN1) (Smith et al., 1999; Yokoyama et al., 2002);
rabbit anti-Drosophila Myb (generous gift from J. Lipsick); mouse
monoclonal anti-actin (C4) (Chemicon International); goat anti-
menin (C19) (Santa Cruz Biotechnology, Inc.); and rabbit anti-menin
(BL342) (Bethyl Laboratories, Inc.). Rabbit anti-FLAG (F-7425) anti-
body and agarose affinity beads coupled to mouse anti-Flag (M2)
monoclonal antibody were purchased from Sigma.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation was performed as previously
described (Weinmann and Farnham, 2002). After one round of im-
munoprecipitation with anti-MLLN (rpN1), anti-Drosophila Myb or
anti-menin (BL342) antibodies, the precipitates were reverse-cross-
linked and treated with proteinase K. The DNA was purified by phe-
nol/chloroform extraction, precipitated, and dissolved in TE. PCR
was performed for 35 cycles using primer pairs specific for up-
stream genomic regions of each gene. Primer sequences and PCR
conditions are available upon request.
Vector Construction
The expression vectors for various MLL-ENL mutants were gener-
ated by restriction enzyme digestion or PCR-based mutagenesis
using pMSCV-FLAG-MLL-ENLC (Ayton and Cleary, 2003) as tem-
plate. The expression vectors for GAL4 fusion proteins were con-
structed by PCR using pM (Clontech) as template and cloned into
pMSCV-puro vector (Clonetech). pMSCV-ires-puro was created by
assembling the IRES element from pMYs-IG (generous gift from T.
Kitamura) into pMSCV-puro vector. The Cre-ERtam cDNA fragment
from pBSIIKS+ K14CreERtam vector (generous gift from E. Fuchs)
was then inserted into pMSCV-ires-puro to create pMSCV-Cre-
ERtam-ires-puro. pMSCV-neo constructs encoding MLL-GAS7,
MLL-AF10, and E2A-HLF were described elsewhere (Ayton and
Cleary, 2003; DiMartino et al., 2002; So et al., 2003).
Myeloid Progenitor Transformation Assays
Mouse bone marrow cells were harvested from leg bones, and cells
expressing surface c-kit were purified by auto-MACS using a PE-
conjugated anti-c-kit antibody (2B8, BD) and anti-PE magnetic
beads (Miltenyi Biotech). Purified cells were used for myeloid pro-
genitor transformation assays as previously described (Lavau et al.,
1997) with minor modifications. For secondary transductions, 105
cells were infected with retrovirus by spinoculation and cultured
overnight in 2 ml of methylcellulose medium (M3231, Stemcell
Technologies) containing SCF, IL-3, IL-6, and GM-CSF. Puromycin
(1 g/ml) was added to the culture on the next day and the cells
were plated in 6-well dishes. After 4–6 days, puromycin-resistant
cells were replated in the presence of 1 nM of 4-OHT (Sigma) for
induction of Cre-ERtam for further analysis. Transplantation of trans-
duced progenitors into lethally irradiated, syngeneic recipients was
performed as described previously (Lavau et al., 1997), with the
exception that donor C57BL/6 mice were transgenic for eGFP
(Wright et al., 2001) and progenitors were incubated in RPMI 1640
medium supplemented with 20% FCS, 20% WEHI supernatant, 20
ng/ml SCF, 10 ng/ml IL-6, and 1mg/ml G418 for 5 days following
spinoculation prior to transplantation.
Genotyping
Mice containing a floxed Men1 gene (Hughes et al., 2004) were
maintained as homozygotes through intercross matings. Cre-medi-
ated excision of the Men1 gene was assessed by PCR using a
primer pair (5#-CTTGGCTGGACGTAAACTCCTCTTCAGACC-3#/5#-
GATGCTAAAGGGTCCTCCCTGTCT-3#).
Flow Cytometry and DNA Content Analysis
For FACS analysis, cells were obtained by bone marrow aspirate
from transplanted mice as described (Verlinden et al., 1998), or re-
suspension in PBS from methylcellulose culture, and then washed
and suspended in 3% FCS in PBS. Antibodies against Mac-1 [Cy7APC
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(onjugated (M1/70, BD)] or TER119 (PE conjugated, BD) were
dded to the cell suspension at a dilution of 1:200 and 1:100, re-
pectively. After 30 min of incubation on ice, cells were washed,
uspended in 3% FCS in PBS containing 1g/ml of propidium io-
ide (PI, Sigma), and analyzed by flow cytometry.
For DNA content analysis, ice-cold 70% ethanol (5 ml) was
dded with vortexing to cells suspended in PBS (100 l) followed
y incubation on ice for at least 30 min. Cells were washed with
BS, suspended in 200 l, mixed with 10 l of 10 mg/ml RNase A,
nd then incubated at 37°C for 20 min. Following addition of 500
l of PI solution (0.1% trisodium citrate, 50 g/ml PI) and incuba-
ion for 10 min at 4°C, the cells were analyzed by flow cytometry.
eal-Time Quantitative PCR Analysis of Gene Expression
otal RNA was purified using an RNeasy mini kit (Qiagen), and 1 g
as reverse-transcribed using an oligo-dT primer and Superscript
irst-Strand Synthesis System for RT-PCR (Invitrogen) according
o the manufacturer’s instructions. The reaction products were
iluted (10×) with TE, and 2 l was subjected to real-time PCR,
hich was performed in triplicate using Taqman probes and the
BI Prism 7700 sequence detection system. Taqman probes for
oxa7 (Mm00657963_m1), Hoxa9 (Mm00439364_m1), p27Kip1
Mm00438167_g1), and b-Actin (Mm00607939_m1) were purchased
rom Applied Biosystems. Expression levels of Hoxa7, Hoxa9, and
27Kip1 relative to that of b-Actin were calculated using a standard
urve and the relative quantitation method as described in ABI
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